Key result
Endothelial dysfunction plays a key role in diabetic atherosclerosis, though definitive clinical trial evidence regarding the cardiovascular benefits of therapies targeting this condition remains limited.
Endothelial dysfunction is a key early mechanism of atherosclerosis in diabetes, with ACE inhibitors showing potential to alter disease progression, though evidence for other therapies remains inconclusive.
No takes yet. Share an insight, caveat, or question.
Supports endothelial dysfunction as a therapeutic target in diabetic atherosclerosis; leaves open whether targeting it improves cardiovascular outcomes.
J. Calles-Escandon (2001) conducted a review in Diabetes mellitus. Various therapeutic interventions was evaluated. Endothelial dysfunction plays a key role in diabetic atherosclerosis, though definitive clinical trial evidence regarding the cardiovascular benefits of therapies targeting this condition remains limited.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: